Narval
Featured Article
Monoclonal antibody treatments have many challenges — Narval is fixing them
Monoclonal antibodies are the building blocks of some of the most important medical treatments in the world. But they have limitations. For example, the large size of the molecules mean monoclonal antibody treatments usually need to be injected — even for eye conditions. Narval CEO Jose Luis Nuno describes the first time he saw a…
10:04 am PDT • September 19, 2023
Startups
Introducing the 2023 Startup Battlefield Top 20 onstage at TechCrunch Disrupt
8:00 am PDT • September 19, 2023
I’m thrilled to announce the Startup Battlefield 20 companies, pitching at TechCrunch Disrupt 2023. After last year’s big hit, TechCrunch editorial hand-selected 200 startups, out of thousands of applicants, to…
